A novel synthetic inhibitor of CDC25 phosphatases: BN82002

• Published in: Cancer research (Chicago, Ill.) Vol. 64; no. 9; pp. 3320 - 3325
• Main Authors: BREZAK, Marie-Christine, QUARANTA, Muriel, LANCO, Christophe, KASPRZYK, Philip G, PREVOST, Gregoire P, DUCOMMUN, Bernard, MONDESERT, Odile, GALCERA, Marie-Odile, LAVERGNE, Olivier, ALBY, Frédéric, CAZALES, Martine, BALDIN, Véronique, THURIEAU, Christophe, HARNETT, Jeremiath
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01-05-2004
• Subjects: Animals; Antineoplastic Agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; cdc25 Phosphatases; cdc25 Phosphatases - antagonists & inhibitors; cdc25 Phosphatases - biosynthesis; cdc25 Phosphatases - genetics; Cell Cycle; Cell Cycle - drug effects; Cell Cycle Proteins; Cell Cycle Proteins - biosynthesis; Cell Cycle Proteins - genetics; Cell Division; Cell Division - drug effects; Cell Line, Tumor; Cellular Biology; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Enzyme Inhibitors - pharmacology; Ethylamines; Female; HeLa Cells; Humans; Life Sciences; Medical sciences; Mice; Mice, Nude; Mitosis; Mitosis - drug effects; Nitro Compounds; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - enzymology; Pancreatic Neoplasms - pathology; Pharmacology. Drug treatments; Tumors; Xenograft Model Antitumor Assays; Phosphoric monoester hydrolases; Hydrolases; Esterases; Inhibitor; Synthetic product; Enzyme
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-03-3984

CDC25 dual-specificity phosphatases are essential regulators that dephosphorylate and activate cyclin-dependent kinase/cyclin complexes at key transitions of the cell cycle. CDC25 activity is currently considered to be an interesting target for the development of new antiproliferative agents. Here we report the identification of a new CDC25 inhibitor and the characterization of its effects at the molecular and cellular levels, and in animal models. BN82002 inhibits the phosphatase activity of recombinant human CDC25A, B, and C in vitro. It impairs the proliferation of tumoral cell lines and increases cyclin-dependent kinase 1 inhibitory tyrosine phosphorylation. In synchronized HeLa cells, BN82002 delays cell cycle progression at G1-S, in S phase and at the G2-M transition. In contrast, BN82002 arrests U2OS cell cycle mostly in the G1 phase. Selectivity of this inhibitor is demonstrated: (a) by the reversion of the mitotic-inducing effect observed in HeLa cells upon CDC25B overexpression; and (b) by the partial reversion of cell cycle arrest in U2OS expressing CDC25. We also show that BN82002 reduces growth rate of human tumor xenografts in athymic nude mice. BN82002 is a original CDC25 inhibitor that is active both in cell and animal models. This greatly reinforces the interest in CDC25 as an anticancer target.